Current MS Treatments

Size: px
Start display at page:

Download "Current MS Treatments"

Transcription

1 Current MS Treatments Yves Lapierre, MD Director Multiple Sclerosis Clinic INM/HNM Over the past 60 years and particularly since the 1960s, the combined efforts of many participants: - donors, MS Societies, - government agencies - MS clinic clinicians and scientists and pharmaceutical industry scientists - and all the study participants and patients have contributed to the emergence of new theories that led to new treatments. 1

2 The Past Jean-Martin Charcot described MS in 1868 He could not identify a cause but observed inflammation around blood vessels, loss of myelin, relative axon preservation and dissemination in the central nervous system. He also recognized the predominance of women, the age group, and the influence of stress and infections. Progression was deemed unavoidable and treatments disappointing:... need I say more about treatment. The time has not yet come when such a thing could be seriously considered. Today, 150 years later, we have developed and use epidemiology, (epi)genetics, molecular biology, immunology, experimental pathology and imaging. This is where we are now with regard to mechanisms and treatments. MS Treatments Treatment of attacks (relapses) Treatments for symptoms: spasticity, pain, sphincter problems, depression, etc. General measures: lifestyle, exercise, etc. Basic treatments 2

3 First-Generation Treatments Injections Avonex Betaseron/Extavia Copaxone Rebif INTERFERONS and GLATIRAMER ACETATE Properties of Interferons IFN Secreted naturally in the human body by many cells, including white blood cells. Cytokine (protein) interferes with virus replication, hence the term interferon, and with tumour growth. In medicine, 3 interferons are of interest:, and Beta-IFN: reduces harmful proinflammatory markers by stimulating suppressor lymphocytes. Also has a stabilizing effect on the blood-brain barrier (BBB) 3

4 Properties of Glatiramer Acetate (Copaxone) Polymer, combination of 4 amino acids that imitate a short sequence found in myelin basic protein Modulates the immune system to reduce bad lymphocytes (Th1) entering the central nervous system This reduces the number of attacks (29-32%), relapse severity and the number of new plaques on MRI Clinical Testing RRMS Annual Relapse Rate (2 years) Complications with Interferons Injectable Injection-site reactions (decreasing) Flu-like reactions (aches, etc., also decreasing) Headaches (in people prone to migraines) Monitoring Liver function and CBC, monthly X 6 then longer intervals Thyroid function Generally safe in the long term; liver, CBC 4

5 Complications with Glatiramer Acetate Injectable Injection-site reactions (slight) Systemic reactions: retrosternal tightening/pain, anxiety, minutes, soon after injection in about 15% of patients always benign Lipoatrophy at injection sites, medium/long-term for a percentage of patients Allergy: rare/very rare Monitoring None Recently available Perfusion Tysabri (2006) Lemtrada (2013) Oral Gilenya (2011) Tecfidera (2013) Aubagio (2013) Basic Treatments: Second Generation MOST RECENT TREATMENTS Tysabri (natalizumab) 5

6 Tysabri (natalizumab) Monoclonal antibody binds to the alpha 4 integrin adhesion molecule and blocks the entry of lymphocytes into the central nervous system Approved for relapsing/remitting MS that is severe or resistant to other first-line treatments May be used as a first-line treatment in very severe cases AFFIRM and SENTINEL In these studies, Natalizumab reduced the number of relapses, the number of new plaques on MRI and delayed progression of the disease 68% fewer relapses and stable progression based on EDSS Can improve fatigue and attention disorders Adverse effects (non-pml): Allergy: infrequent (< 1%) Antibodies neutralize the drug (6%) Perfusion site reactions Liver enzymes occasionally high, require monitoring Jneurol, 18 mars 2009, Hutchinson. AFFIRM; n engl j med 354;9 2 mars, 2006 SENTINEL; n engl j med 354;9; march 2, 2006 TYSABRI: ANNUAL RELAPSE RATE 68% reduction compared to placebo Annual Relapse Rate (CI 95%) P< % 0.78 P< % Placebo n=315 TYSABRI n= P< % Years 0 2 Years 0 1 Years 1 2 Polman CH, et al. N Engl J Med. 2006;354: ; AFFIRM Study 6

7 AFFIRM: Lasting Improvement of Disability in Patients with Highly Active MS and EDSS 2.0* Cumulative Probability of Sustained Improvement With Natalizumab, >1 in 3 patients improved in 2 years Boosted probability of improvement 143% Adjusted HR = 2.43 (95% CI: ) P=0.045 Natalizumab 35.5% Placebo 15.4% In weeks since onset Number of Patients at Risk Placebo Natalizumab *Sustained improvement: 1.0-point reduction in EDSS score; highly active MS ( 2 relapses reported in the year before study entry and 1 gadolinium-enhanced lesion at the time of study entry). EDSS=Expanded Disability Status Scale; HR=hazard ratio; CI=confidence interval; MS=multiple sclerosis. Phillips JT et al. Mult Scler. 2011;17: ; Munschauer F et al. Presented at AAN; April 25 May 2, 2009; Seattle, WA. P % Free of clinical MS activity 71% No Relapses 95% No Gd+ Lesions AFFIRM: Natalizumab Increased the Percentage of Patients Without Clinically Active MS and No MRI Activity 37% No MS Activity 58% No Activity on MRI 84% No Progression 58% No T2 Lesions Patients Free of Activity for 2 Years Placebo (n=304) 7% P< Natalizumab (n=600) 37% P<0.0001, natalizumab vs placebo, for all individual and combined disease measures. MRI=magnetic resonance imaging; Gd+=gadolinium-enhancing. Havrdová E et al. Lancet Neurol. 2009;8: STRATA: Low Annual Relapse Rate up to 4 Years Consistent with the AFFIRM Study Rate Originally Placebo Originally Natalizumab Unadjusted Annual Relapse Rate 0,71 n=381 n=707 n=381 n=707 n=328 n=641 Stop / Suspend Treatment n=385 0,31 n=709 n=282 n=584 Originally Placebo then on Natalizumab n=249 n=528 n=244 n=519 n=203 n=456 n=385 n= ,22 0,17 0,22 0,22 0,21 0,21 0,17 0,16 0 0,14 0,13 0,11 0,11 Years 1 Year 2 Years 3 Years 4 Years 5 *Includes data on patients dosed with natalizumab; includes all available on-treatment relapse data. Goodman A et al. Presented at ECTRIMS; October 19 22, 2011; Amsterdam, Netherlands. P Sept

8 Overall safety Overview of Clinical Trials Adverse effects are generally slight and resolve spontaneously: Headaches, fatigue, urinary infections, arthralgias, flu-like symptoms, etc. Serious adverse effects are comparable to placebo Low rate of serious hypersensitivity reaction (1.1%) No high risk of cancer or depression Infections Rare cases of PML and other opportunistic infections Some herpes zoster infection/reactivation cases Stoppage due to adverse effects comparable in groups 4% placebo, 6% Natalizumab AE=adverse event; PML=progressive multifocal leukoencephalopathy. Polman CH et al. N Engl J Med. 2006;354: ; Rudick RA et al. N Engl J Med. 2006;354: ; Yousry TA et al. N Engl J Med ;354: LL Educational resource provided in response to unsolicited request (Content current 10/17/2012) MOST RECENT TREATMENTS Lemtrada (alemtuzumab) 8

9 Alemtuzumab: Active Mechanism Can Explain Rebalancing of the Immune System Alemtuzumab is a monoclonal antibody that, by selectively targeting the CD52 antigen, depletes the T and B lymphocytes in the blood 1-3 ; this is followed by a distinctive repopulation pattern that is thought to rebalance the immune system 2,3. These pharmacodynamic variations may partially explain its effect on multiple sclerosis (MS) 4. Selection Depletion Repopulation The mechanism for the therapeutic effects of alemtuzumab in MS is unclear. 1. Fox EJ. Expert Rev Neurother 2010; 10: ; 2. Jones JL et al. Brain 2010:133; ; 3. Cox AL et al. Eur J Immunol 2005:35; ; 4. Données internes de Genzyme Corporation. Alemtuzumab is thought to rebalance the immune system in remitting-relapsing MS Cible les lymphocytes T et B Atténue l inflammation dans la SEP Diminue l activité de la maladie dans la SEP The exact active mechanism of alemtuzumab is unclear. 1. Fox EJ. Expert Rev Neurother 2010; 10(12): ; 2. Jones JL et al. Brain 2010:133(pt 8); ; 3. Cox AL et al. Eur J Immunol 2005;35(11); ; 4. Données internes de Genzyme/sanofi, Cambridge, MA. Annual Relapse Rate (Main Coparameter) 0.6 CARE-MS I IFNß-1a sc 0.7 Relapse reduction: 54.9% p< Alem. 12 mg 0.6 CARE-MS Il 0.7 Relapse reduction: 49.4% p< Adjusted ARR (95% CI) Adjusted ARR (95% CI) Years Years 0 2 Alem.=alemtuzumab; ARR=annual relapse rate; CI= confidence interval; IFNß-1a s.c.=interferon beta-1a subcutaneous 1. Coles AJ et al. ECTRIMS 2011; 2. Cohen JA et al. AAN

10 Common Side Effects of Lemtrada Most patients treated with Lemtrada experience side effects during the infusion or within the next 24 hours For most people, reactions are mild, but severe reactions may occur Your health professional can prescribe medications to help limit Lemtrada s side effects, including: Methylprednisolone (1,000 mg) for the first three 3 days of each cycle Acyclovir (200 mg) twice a day or the equivalent the first day of each cycle and for at least 1 month Antihistamines and/or antipyretics Reserved for the use of Canadian health professionals Common Side Effects of Lemtrada The most common side effects of Lemtrada are: Headaches and dizziness Skin rash, hives and itching Fever Nausea and vomiting Difficulty sleeping Lemtrada Safety: Autoimmune Side Effects Serious and fatal autoimmune conditions have arisen during clinical trials and after 5 years of follow-up Autoimmune side effects are disorders that occur when the organism is attacked by its own immune system Lemtrada may cause your immune system to attack parts of your body, including blood, thyroid and kidneys. Lemtrada s serious autoimmune side effects may include: Idiopathic thrombocytopenic purpura (ITP causing a low blood platelet count): serious but diagnosable and treatable, < 1 % Thyroid disorders, always treatable, approximately 19% Kidney disease: serious, 0.3% Other blood disorders (in rare cases) Reserved for the use of Canadian health professionals 10

11 DRUGS IN PILL FORMAT Gilenya (Fingolimod) HO HO NH 2 Gilenya (Fingolimod) S1P1 receptor inhibiter Active mechanism Redistributes lymphocytes from blood to lymphatic organs. Penetrates the CNS, acts on neurons. Possible direct regenerative effect on oligodendrocytes Administration Oral pill 0.5 mg, once a day Horga A, Montalban X. Expert Rev Neurotherapeutics. 2008; 8: Blood FTY720 Inhibits Lymphocyte Transmigration out of Lymph Nodes Efferent Lymph Normal Lymphocytes circulate freely between blood and the efferent lymph Blood Lymph Node The lymph node s endothelial barrier allows lymphocytes to transmigrate out of the node Efferent Lymph FTY720 Lymphocytes remain trapped in the lymph node when the endothelial barrier constricts Lymph Node Restriction of the endothelial barrier by continuous FTY720 stimulation of the S1P 1 receptors in the node s endothelium prevents lymphocyte migration out of the nodes. 11

12 Annual Relapse Rate FREEDOMS (phase III study) Main Criterion: Annual Relapse Rate 54% vs 60% vs placebo placebo p < p < Placebo (n = 418) Fingolimod 0.5 mg (n = 425) Fingolimod 1.25 mg (n = 429) ARR was also reduced both in patients never treated and in patients who previously took an IMD (p < 0.01 for all comparisons) ITT Population Binomial regression model adjusted by treatment group, country, number of relapses in the previous two years and for EDSS at onset ARR, annual relapse rate; IMD, immunomodulator Fingolimod Side Effects Fingolimod may: Cause a reversible bradycardia (3.5% v. 1.0% with placebo) We must observe all patients for 6 hours after the first dose Cause macular edema (0.4% v. 0.1% with placebo) We must perform an ophthalmic evaluation 3 to 4 months after beginning treatment Footnote: UO = Undesirable occurrence; VZV = varicella zoster virus Health Canada Drug Product Database Available at: Consulted on April 1, 2011 EI = événement indésirable; VZV = virus varicelle-zona Santé Canada. Base de données sur les produits pharmaceutiques. Disponible au : Consulté le 1 er avril Fingolimod Side Effects Increase in liver enzymes (3.3% v. 0.2% with placebo) We must monitor transaminase and bilirubin levels before treatment every three months during the first year and periodically thereafter Slight increase in the risk of lower respiratory infections (0.5% v. 0.2% with placebo) and herpes virus (8.7% v. 7.9% with placebo) We need to check the CBC and VZV serostatus before starting treatment 12

13 FREEDOMS (phase III) Security : Summary Cardiovascular Bradycardia was frequent, but usually asymptomatic, transient and self-limiting Atrioventricular blocks were uncommon, usually asymptomatic, transient and self-limiting Both events were seen following administration of the first dose of fingolimod A mild increase (1-3 mmhg ) in blood pressure was observed Infections Overall incidence of infections, including herpesvirus infections, was similar in all three groups Lower respiratory tract infections (bronchitis and pneumonia) occurred more frequently in the fingolimod groups compared with placebo The reduction in peripheral lymphocyte count was not associated with an increase in infections Macular edema 7 cases reported, all in the fingolimod 1.25 mg group The majority occurred within the first 3 months of treatment and resolved after study drug discontinuation Neoplasms Malignant neoplasms reported in 4 patients receiving fingolimod 0.5 mg, 4 patients receiving fingolimod 1.25 mg, and 10 patients in the placebo group The study findings do not suggest an increased risk of cancer with the use of fingolimod S1P 1, sphingosine 1-phosphate receptor subtype 1 DRUGS IN PILL FORMAT Tecfidera (dimethyl fumarate) BG 12: Define Study BG 12/dimethyl fumarate (new generation) Neuroprotection and anti-inflammatory effects Activates the Nrf2 transcription factor pathway that has neuroprotective effects (stimulates the Antioxidant Response Element pathway) Inhibits some cytokines and adhesion molecules 13

14 Capsules containing tiny enterosoluble DMF pills Monomethyl Fumarate (MMF) Dimethyl Fumarate (DMF) and the Fumarates Fumaric Acid Dimethyl Fumarate Dawson K et al. Presented at CMSC; May 27 30, 2009; Atlanta, GA, USA. S H Fumaric acid is a natural molecule, essential for oxidative respiration (Krebs/citric-acid cycle). Dimethyl fumarate is formulated as oral, enterosoluble microcrystals contained in a capsule. Dimethyl fumarate is quickly converted presystemically into monomethyl fumarate (MMF). DEFINE (Determination of the Efficacy and Safety of Oral Fumarate IN RElapsing-Remitting MS) Phase III randomized, double-blind, placebo-controlled clinical trial: 2 years, multisite, 1234 patients Assessed the efficacy and safety of BG-12 compared to placebo in patients with remitting-relapsing MS 2 BG-12, 240 mg twice daily (BID) and 3 times daily (TID) reduced: Risk of attack by 49% and 50%, respectively (P<0.0001) Annual relapse rate was 53% and 48% (P<0.0001) Disability progression was 38% (P=0.0050) and 34% (P=0.0128) BG-12 significantly reduced lesions on MRI after 2 years (MRI group): Gadolinium-enhancing (Gd+) lesions New/expanding T2 lesions New T1 hypointense lesions 2 Gold et al. ECTRIMS 2011 (oral presentation #95). Integrated Analysis: Annual Relapse Rate and Percentage of Relapsed Patients DMF bid=43% reduction of risk, P DMF tid=47% reduction of risk, P % reduction vs placebo P * 49% reduction vs placebo P * Placebo DMF bid DMF tid BL Study Time (weeks) 42 Integrated ITT population; only relapses confirmed by the INEC are included in the analysis. *P value based on Poisson regression (due to underdispersion using negative binomial distribution) adjusted for baseline EDSS score ( 2.0 vs >2.0), study, region, number of relapses in the 1 year prior to study entry, and baseline age (<40 vs 40 years); P value based on Cox proportional hazards model; Kaplan-Meier estimate of the proportion of subjects relapsed within 2 years. Gold R et al. Presented at ECTRIMS; October 10 13, 2012; Lyon, France. S

15 GI Adverse Effects in the First 3 Months of Treatment with 240 mg BID Adverse Effects. chez 769 patients. Abdominal Pain Nausea/ Vomiting Diarrhea All cases, n Severity, n (%) Slight Moderate Severe 68 (56) 42 (35) 11 (9) 65 (54) 49 (41) 6 (5) 49 (63) 26 (33) 3 (4) Symptom therapy n (%) 46 (38) 39 (33) 20 (26) Resolved, n (%) 113 (93) 114 (95) 75 (96) denominator for percentages; patients may have experienced more than one event; events may have resolved at any time during the study. GI events included the preferred terms in the level 2 subordinate standardized MedDRA queries gastrointestinal nonspecific inflammations or gastrointestinal nonspecific symptoms and therapeutic procedures. Bar-Or A et al. Presented at Latin-American Congress of Multiple Sclerosis; November, 28 30, 2012; Rio de Janeiro, Brazil Conclusions Dimethyl fumarate mainly acts via the Nrf2 pathway, which governs antiinflammatory and cytoprotective responses to oxidative stress. Efficacy results for DMF bid and tid were largely comparable. Compared to placebo, DMF bid significantly reduced disease activity, clinically and on MRI, and improved quality-of-life parameters. All causes considered, the incidence of serious or less serious adverse effects and stopping medication because of adverse effects were similar for the both the placebo and DMF groups. However, the most noteworthy adverse effects of the drug were flushing on the face and arms with itching and gastrointestinal events. Incidence peaked in the first months of the study, then decreased. Adverse effects were mostly considered slight or moderate; only 3% and 4%, respectively, of patients stopped the treatment because of flushing and GI symptoms. Nrf2=nuclear factor (erythroid-derived 2)-like 2; Keap1=kelch-like ECH-associated protein. Linker RA et al. Brain. 2011;134: ; Scannevin R et al. J Pharmacol Exp Ther. 2012;341: Fox R et al. N Engl J Med. 2012;367: ; Gold R et al. N Engl J Med. 2012;367: ; Gold R et al. Presented at ECTRIMS; October 10 13, 2012; Lyon, France. S151; Kappos L et al. Presented at AAN; March 16 23, 2013; San Diego, CA. S41.005; Kita M et al. Presented at AAN; March 16 23, 2013; San Diego, CA. P07.092; Havrdova E et al. Presented at AAN; March 16 23, 2013; San Diego, CA. P07.106; Selmaj K et al. Presented at ECTRIMS; October 10 13, 2012; Lyon, France. P484 DRUGS IN PILL FORMAT Teriflunomide (Aubagio) 15

16 Teriflunomide Active mechanism Administration Clinical studies Inhibits proliferation of rapidly dividing cells by inhibiting pyrimidine synthesis. Possible preference for T cells Oral pill once a day:14 mg TENERE (vs Rx44); TOPICS (SCI study); TEMSO; phase III placebocontrolled study; Phase II GA additive and IFN additive Studies ended ~ 2012 Tallantyre E et al. Int MS J. 2008; 15:62 8 Not approved by Health Canada AUBAGIO MD (Teriflunomide) Active Mechanism in MS According to research, AUBAGIO acts differently from other current MS treatments AUBAGIO blocks reproduction of overactive immune cells that may be responsible for inflammation in MS For illustration only. The exact active mechanism in AUBAGIO s therapeutic effect in MS is unknown. Reference: AUBAGIO Monograph. USE RESERVED FOR HEALTH PROFESSIONALS 47 Efficacy of AUBAGIO MD (teriflunomide): Annual Relapse Rate Clinical Trial 1: TEMSO Relapse rate decreased 31% in patients receiving a 14-mg dose of AUBAGIO, compared to controls. Clinical Trial 2: TOWER Relapse rate decreased % 36% in patients receiving a 14-mg dose of AUBAGIO, Reduction of relapses compared to controls. Reference: AUBAGIO Monograph. USE RESERVED FOR HEALTH PROFESSIONALS 48 16

17 Efficacy of AUBAGIO MD (teriflunomide): Number of New Lesions Clinical Trial 1: TEMSO The 14-mg dose of AUBAGIO reduced the number of brain lesions by 80% compared to placebo 1. AUBAGIO Monograph. USE RESERVED FOR HEALTH PROFESSIONALS 49 Most Frequent Adverse Effects of AUBAGIO MD (teriflunomide) Adverse effects in 5% of patients reported with 14 mg AUBAGIO at a rate 1% higher than placebo AUBAGIO 14 mg Adverse Effects (n = 786) Infections and Infestations Flu 9.2% Sinusitis 6.0% Placebo (n = 806) 7.4% 3.8% Blood and lymphatic system disorder Neutropena 6.9% 1.6% Nervous system disorder Paresthesia 8.4% 7.1% Gastrointestinal events Diarrhea (caused dropouts: 0.3%/0.8% in TEMSO/TOWER trials) Nausea Upper abdominal pain 14.4% 12.3% 5.6% 7.8% 7.8% 4.3% Skin and subcutaneous tissue Alopecia (caused dropouts: 1.4%/1.6% in TEMSO/TOWER trials) Acne 14.1% 5.0% 4.3% 3.3% Tests and analyses Elevated alanine aminotransferase levels (caused dropouts: 2.2 %/2.4 % in TEMSO/TOWER trials) This list of adverse effects is not exhaustive. For any unexpected effects that occur during treatment with AUBAGIO, contact your physician or MS One on One program nurse. 14.0% 7.7% 50 New Treatments 5 new treatments have appeared since In placebo-controlled studies and others using an active comparator, the results suggest, and in many cases confirm, greater efficacy for most of the new products. Aubagio, an oral treatment, is as effective as the first generation treatments. The adverse-effect profiles of the new drugs are very different from the previous drugs and require different monitoring, in some cases much more intensive. Given these differences, every drug must be prescribed after appropriate education and discussion with the health care team, and based on the disease type and severity, previous treatments, comorbidities, lifestyle, preferences, refunds, etc. 17

18 Summary In recent decades, tremendous progress has been made in MS research but much remains to be done. Challenges: the cause(s), control of all forms of the disease, the cure?, rehabilitation, remyelination, stem cells, prevention Since1995, 12 basic treatments have been introduced and progress continues Thank You 18

Treatments for MS: Immunotherapy. Gilenya (fingolimod) Glatiramer acetate (Copaxone )

Treatments for MS: Immunotherapy. Gilenya (fingolimod) Glatiramer acetate (Copaxone ) Treatments for MS: Immunotherapy There are currently several disease-modifying therapies approved for people with MS in Australia. These therapies, called immunotherapies, work to reduce disease activity

More information

Progress in MS: Current and Emerging Therapies

Progress in MS: Current and Emerging Therapies Progress in MS: Current and Emerging Therapies Presented by: Dr. Kathryn Giles, MD MSc FRCPC The MS Society gratefully acknowledges the grant received from Biogen Idec Canada, which makes possible the

More information

Laquinimod Polman, C. et al. Neurology 2005;64:987-991

Laquinimod Polman, C. et al. Neurology 2005;64:987-991 Laquinimod Polman, C. et al. Neurology 2005;64:987-991 Multicenter, double-blind, randomized trial, patients with RR MS received 0.1 mg or 0.3 mg laquinimod or placebo as three daily tablets for 24 weeks

More information

Committee Approval Date: December 12, 2014 Next Review Date: December 2015

Committee Approval Date: December 12, 2014 Next Review Date: December 2015 Medication Policy Manual Policy No: dru299 Topic: Tecfidera, dimethyl fumarate Date of Origin: May 16, 2013 Committee Approval Date: December 12, 2014 Next Review Date: December 2015 Effective Date: January

More information

Understanding How Existing and Emerging MS Therapies Work

Understanding How Existing and Emerging MS Therapies Work Understanding How Existing and Emerging MS Therapies Work This is a promising and hopeful time in the field of multiple sclerosis (MS). Many new and different therapies are nearing the final stages of

More information

Personalised Medicine in MS

Personalised Medicine in MS Personalised Medicine in MS Supportive Evidence from Therapeutic Trials Ludwig Kappos Neurology and Department of Biomedicine University Hospital CH-4031 Basel LKappos@uhbs.ch Established partially effective

More information

News on modifying diseases therapies. Michel CLANET CHU Toulouse France ECTRIMS

News on modifying diseases therapies. Michel CLANET CHU Toulouse France ECTRIMS News on modifying diseases therapies Michel CLANET CHU Toulouse France ECTRIMS Current treatment strategies Future oral treatments Future non oral treatments Drug safety and risks CIS at risk of MS Active

More information

New Treatment Options for MS Patients: Understanding risks versus benefits

New Treatment Options for MS Patients: Understanding risks versus benefits New Treatment Options for MS Patients: Understanding risks versus benefits By Michael A. Meyer, MD Department of Neurology, Sisters Hospital, Buffalo, NY Objectives: 1. to understand fundamentals of MS

More information

New treatments in MS What s here and what s nearly here

New treatments in MS What s here and what s nearly here 5 th MS Research Day, June 14 th 2014 New treatments in MS What s here and what s nearly here David Miller Queen Square MS Centre at UCL and UCLH Course of MS and its treatment Relapsing remitting Disability

More information

Disease Modifying Therapies for MS

Disease Modifying Therapies for MS Disease Modifying Therapies for MS The term disease-modifying therapy (DMT) means a drug that can modify or change the course of a disease. In other words a DMT should be able to reduce the number of attacks

More information

A neurologist would assess your eligibility and suitability for the DMTs.

A neurologist would assess your eligibility and suitability for the DMTs. Choices Disease Modifying Treatments Disease modifying treatments (DMTs) are medications which modify the disease course. They target inflammation and are designed to reduce the damage caused by relapses.

More information

Medication Policy Manual. Topic: Aubagio, teriflunomide Date of Origin: November 9, 2012

Medication Policy Manual. Topic: Aubagio, teriflunomide Date of Origin: November 9, 2012 Medication Policy Manual Policy No: dru283 Topic: Aubagio, teriflunomide Date of Origin: November 9, 2012 Committee Approval Date: December 12, 2014 Next Review Date: December 2015 Effective Date: January

More information

New and Emerging Immunotherapies for Multiple Sclerosis: Oral Agents

New and Emerging Immunotherapies for Multiple Sclerosis: Oral Agents New and Emerging Immunotherapies for Multiple Sclerosis: Oral Agents William Tyor, M.D. Chief, Neurology Atlanta VA Medical Center Professor, Department of Neurology Emory University School of Medicine

More information

J.P. Morgan Cazenove Therapeutic Seminar

J.P. Morgan Cazenove Therapeutic Seminar Jannan, MS J.P. Morgan Cazenove Therapeutic Seminar David Meeker - CEO, Genzyme June 25, 2012 Forward Looking Statements This presentation contains forward-looking statements as defined in the Private

More information

Medication Policy Manual. Topic: Aubagio, teriflunomide Date of Origin: November 9, 2012

Medication Policy Manual. Topic: Aubagio, teriflunomide Date of Origin: November 9, 2012 Medication Policy Manual Policy No: dru283 Topic: Aubagio, teriflunomide Date of Origin: November 9, 2012 Committee Approval Date: December 11, 2015 Next Review Date: December 2016 Effective Date: January

More information

Disclosures. Consultant and Speaker for Biogen Idec, TEVA Neuroscience, EMD Serrono, Mallinckrodt, Novartis, Genzyme, Accorda Therapeutics

Disclosures. Consultant and Speaker for Biogen Idec, TEVA Neuroscience, EMD Serrono, Mallinckrodt, Novartis, Genzyme, Accorda Therapeutics Mitzi Joi Williams, MD Neurologist MS Center of Atlanta, Atlanta, GA Disclosures Consultant and Speaker for Biogen Idec, TEVA Neuroscience, EMD Serrono, Mallinckrodt, Novartis, Genzyme, Accorda Therapeutics

More information

Disease Modifying Therapies for MS

Disease Modifying Therapies for MS Disease Modifying Therapies for MS The term disease-modifying therapy means a drug that can modify or change the course of a disease. In other words a DMT should be able to reduce the number of attacks

More information

Which injectable medication should I take for relapsing-remitting multiple sclerosis?

Which injectable medication should I take for relapsing-remitting multiple sclerosis? Which injectable medication should I take for relapsing-remitting multiple sclerosis? A decision aid to discuss options with your doctor This decision aid is for you if you: Have multiple sclerosis Have

More information

Integrating New Treatments: A Case Based Approach

Integrating New Treatments: A Case Based Approach Integrating New Treatments: A Case Based Approach JILL CONWAY, MD, MA, MSCE DIRECTOR, MS CENTER DIRECTOR, NEUROLOGY CLERKSHIP AT UNCSOM- CHARLOTTE CAMPUS CAROLINAS HEALTHCARE CENTER Objectives Provide

More information

Department of Health. Rheynn Slaynt. Clinical Recommendations Committee

Department of Health. Rheynn Slaynt. Clinical Recommendations Committee Recommendation 06/13 Department of Health Rheynn Slaynt Clinical Recommendations Committee The Isle of Man Department of Health recommend Gilenya (fingolimod) as a HIGH PRIORITY - as an option for the

More information

fingolimod, 0.5mg, hard capsules (Gilenya ) SMC No. (992/14) Novartis Pharmaceuticals UK

fingolimod, 0.5mg, hard capsules (Gilenya ) SMC No. (992/14) Novartis Pharmaceuticals UK fingolimod, 0.5mg, hard capsules (Gilenya ) SMC No. (992/14) Novartis Pharmaceuticals UK 08 August 2014 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises

More information

Natalizumab (Tysabri)

Natalizumab (Tysabri) Natalizumab (Tysabri) Spirella Building, Letchworth, SG6 4ET 01462 476700 www.mstrust.org.uk reg charity no. 1088353 Natalizumab (Tysabri) Date of issue: July 2010 Review date: July 2011 Contents Section

More information

Medication Policy Manual. Topic: Gilenya, fingolimod Date of Origin: November 22, 2010

Medication Policy Manual. Topic: Gilenya, fingolimod Date of Origin: November 22, 2010 Medication Policy Manual Policy No: dru229 Topic: Gilenya, fingolimod Date of Origin: November 22, 2010 Committee Approval Date: December 11, 2015 Next Review Date: December 2016 Effective Date: January

More information

Lemtrada (alemtuzumab)

Lemtrada (alemtuzumab) Lemtrada (alemtuzumab) Policy Number: 5.02.517 Last Review: 08/2015 Origination: 08/2015 Next Review: 08/2016 Policy BCBSKC will provide coverage for Lemtrada (alemtuzumab) when it is determined to be

More information

Version History. Previous Versions. Drugs for MS.Drug facts box fingolimod Version 1.0 Author

Version History. Previous Versions. Drugs for MS.Drug facts box fingolimod Version 1.0 Author Version History Policy Title Drugs for MS.Drug facts box fingolimod Version 1.0 Author West Midlands Commissioning Support Unit Publication Date Jan 2013 Review Date Supersedes/New (Further fields as required

More information

Drug Class Review. Disease-modifying Drugs for Multiple Sclerosis. Single Drug Addendum: Fingolimod

Drug Class Review. Disease-modifying Drugs for Multiple Sclerosis. Single Drug Addendum: Fingolimod Drug Class Review Disease-modifying Drugs for Multiple Sclerosis Single Drug Addendum: Fingolimod Final Original Report February 2011 The Agency for Healthcare Research and Quality has not yet seen or

More information

Cost-effectiveness of dimethyl fumarate (Tecfidera ) for the treatment of adult patients with relapsing remitting multiple sclerosis

Cost-effectiveness of dimethyl fumarate (Tecfidera ) for the treatment of adult patients with relapsing remitting multiple sclerosis Cost-effectiveness of dimethyl fumarate (Tecfidera ) for the treatment of adult patients with relapsing remitting multiple sclerosis The NCPE has issued a recommendation regarding the cost-effectiveness

More information

Disease modifying drug therapy

Disease modifying drug therapy Disease modifying drug therapy New edition for 2014-15 We hope you find the information in this book helpful. If you would like to speak with someone about any aspect of MS, contact the MS Trust information

More information

The MS Disease- Modifying Medications

The MS Disease- Modifying Medications The MS Disease- Modifying Medications National MS Society 1 Current as of November 2014. This online brochure is updated with breaking news as required. If you have a printed a copy of this publication,

More information

- Patients treated with alemtuzumab in CARE-MS II were more than twice as likely to experience disability improvement compared to Rebif -

- Patients treated with alemtuzumab in CARE-MS II were more than twice as likely to experience disability improvement compared to Rebif - PRESS RELEASE Significant Improvement in Disability Scores Observed in Multiple Sclerosis Patients Who Received Lemtrada TM* (Alemtuzumab) Compared With Rebif in Phase lll Trial - Patients treated with

More information

National Multiple Sclerosis Society. Disease Modification in Multiple Sclerosis. Current as of January 2, 2013

National Multiple Sclerosis Society. Disease Modification in Multiple Sclerosis. Current as of January 2, 2013 National Multiple Sclerosis Society Disease Modification in Multiple Sclerosis Current as of January 2, 2013 Since 1993, the U.S. Food and Drug Administration (FDA) has approved several medications for

More information

Current and future options of MS treatment Prof. Dr. Karl Vass, AKH Wien

Current and future options of MS treatment Prof. Dr. Karl Vass, AKH Wien Current and future options of MS treatment Prof. Dr. Karl Vass, AKH Wien European Health Forum, Gastein 6 th October 2010 Multiple Sclerosis is the most common neurological disorder in young Caucasian

More information

Has the medication received FDA approval? Yes the FDA approved dimethyl fumarate on March 27, 2013.

Has the medication received FDA approval? Yes the FDA approved dimethyl fumarate on March 27, 2013. Dimethyl Fumarate [formerly called BG-12] (Tecfidera ) CLINICIAN INFORMATION What is the medication? April 2013 Generic: Dimethyl Fumarate [formerly called BG-12] Brand name: Tecfidera The third oral medication

More information

The submission positioned dimethyl fumarate as a first-line treatment option.

The submission positioned dimethyl fumarate as a first-line treatment option. Product: Dimethyl Fumarate, capsules, 120 mg and 240 mg, Tecfidera Sponsor: Biogen Idec Australia Pty Ltd Date of PBAC Consideration: July 2013 1. Purpose of Application The major submission sought an

More information

Genzyme s Multiple Sclerosis Franchise Featured at AAN

Genzyme s Multiple Sclerosis Franchise Featured at AAN PRESS RELEASE Genzyme s Multiple Sclerosis Franchise Featured at AAN - Multiple Presentations Highlight Continuing Progress of AUBAGIO and LEMTRADA Programs - Paris, France March 13, 2013 Sanofi (EURONEXT:

More information

The MS Disease- Modifying Medications

The MS Disease- Modifying Medications The MS Disease- Modifying Medications National MS Society 1 Current as of January 2015. This online brochure is updated with breaking news as required. If you have a printed a copy of this publication,

More information

The MS Disease- Modifying Medications GENERAL INFORMATION

The MS Disease- Modifying Medications GENERAL INFORMATION The MS Disease- Modifying Medications GENERAL INFORMATION Current as of March 2014. This online brochure is updated with breaking news as required. If you have a printed a copy of this publication, please

More information

Pharmacotherapy of Multiple Sclerosis

Pharmacotherapy of Multiple Sclerosis PHARMACY / MEDICAL POLICY 5.01.565 Pharmacotherapy of Multiple Sclerosis Effective Date: July 1, 2016 Last Revised: June 14, 2016 Replaces: Extracted from 5.01.550 RELATED MEDICAL POLICIES: 5.01.556 Rituximab:

More information

Managing Relapsing Remitting MS Risks & benefits of emerging therapies. Dr Mike Boggild The Walton Centre

Managing Relapsing Remitting MS Risks & benefits of emerging therapies. Dr Mike Boggild The Walton Centre Managing Relapsing Remitting MS Risks & benefits of emerging therapies Dr Mike Boggild The Walton Centre MS: Facts and figures Affects 1 in 800 in the UK Commonest cause of acquired neurological disability

More information

ORAL MEDICATIONS FOR MS! Gilenya and Aubagio

ORAL MEDICATIONS FOR MS! Gilenya and Aubagio ORAL MEDICATIONS FOR MS! Gilenya and Aubagio Champions against MS 4/20/13 Alexandra Goodyear, MD Stanford University Oral Medications Since 2010, 3 new oral medications for MS: Gilenya 2010 Aubagio 2012

More information

Committee Approval Date: December 12, 2014 Next Review Date: December 2015

Committee Approval Date: December 12, 2014 Next Review Date: December 2015 Medication Policy Manual Policy No: dru381 Topic: Lemtrada TM, alemtuzumab Date of Origin: December 12, 2014 Committee Approval Date: December 12, 2014 Next Review Date: December 2015 Effective Date: January

More information

What is Multiple Sclerosis? Disease Modifying Therapies. Best of all. Why is treatment so important? Outline and Expectations.

What is Multiple Sclerosis? Disease Modifying Therapies. Best of all. Why is treatment so important? Outline and Expectations. What is Multiple Sclerosis? Disease Modifying Therapies for Relapsing Remitting MS Jeanie Lynn Cote, MD Chronic, auto immune disorder. As a consequence of immune attacks, there is loss of myelin (fatty

More information

Therapeutic Class Overview Multiple Sclerosis Agents

Therapeutic Class Overview Multiple Sclerosis Agents Therapeutic Class Overview Multiple Sclerosis Agents Therapeutic Class Overview/Summary: Several biologic response modifiers are Food and Drug Administration (FDA)- approved for the treatment of relapsing-remitting

More information

New Therapies in MS: Filling up the spaces. Eli Silber Consultant Neurologist Kings College Hospital

New Therapies in MS: Filling up the spaces. Eli Silber Consultant Neurologist Kings College Hospital New Therapies in MS: Filling up the spaces Eli Silber Consultant Neurologist Kings College Hospital What is wrong with the current therapies? The current therapies have limited efficacy 1 st line relapse

More information

Version History. Previous Versions. Policy Title. Drugs for MS.Drug facts box Glatiramer Acetate Version 1.0 Author

Version History. Previous Versions. Policy Title. Drugs for MS.Drug facts box Glatiramer Acetate Version 1.0 Author Version History Policy Title Drugs for MS.Drug facts box Glatiramer Acetate Version 1.0 Author West Midlands Commissioning Support Unit Publication Date Jan 2013 Review Date Supersedes/New (Further fields

More information

Multiple Sclerosis in Practice. An Expert Commentary With Jeffrey Cohen, MD, PhD A Clinical Context Report

Multiple Sclerosis in Practice. An Expert Commentary With Jeffrey Cohen, MD, PhD A Clinical Context Report Multiple Sclerosis in Practice An Expert Commentary With Jeffrey Cohen, MD, PhD A Clinical Context Report Clinical Context: Multiple Sclerosis in Practice Expert Commentary Jointly Sponsored by: and Clinical

More information

teriflunomide, 14mg, film-coated tablets (Aubagio ) SMC No. (940/14) Genzyme Ltd.

teriflunomide, 14mg, film-coated tablets (Aubagio ) SMC No. (940/14) Genzyme Ltd. teriflunomide, 14mg, film-coated tablets (Aubagio ) SMC No. (940/14) Genzyme Ltd. 10 January 2014 (Issued 07 February 2014) The Scottish Medicines Consortium (SMC) has completed its assessment of the above

More information

MEDICAL ASSISTANCE BULLETIN

MEDICAL ASSISTANCE BULLETIN ISSUE DATE May 11, 2015 SUBJECT EFFECTIVE DATE May 18, 2015 MEDICAL ASSISTANCE BULLETIN NUMBER *See below BY Prior Authorization of Multiple Sclerosis Agents Pharmacy Service Leesa M. Allen, Deputy Secretary

More information

RISK EVALUATION AND MITIGATION STRATEGY (REMS)

RISK EVALUATION AND MITIGATION STRATEGY (REMS) Initial REMS Approval: 9/2010 Most Recent Modification: 05/2015 0.5mg capsules Sphingosine 1-phosphate Receptor Modulator Novartis Pharmaceuticals Corporation One Health Plaza East Hanover, NJ 07936 RISK

More information

Multiple Sclerosis Update. Bridget A. Bagert, MD, MPH Director, Ochsner Multiple Sclerosis Center

Multiple Sclerosis Update. Bridget A. Bagert, MD, MPH Director, Ochsner Multiple Sclerosis Center Multiple Sclerosis Update Bridget A. Bagert, MD, MPH Director, Ochsner Multiple Sclerosis Center None Disclosures First of All. Why is my talk in the Neurodegenerative hour? I respectfully object! Case

More information

Alemtuzumab for treating relapsing-remitting multiple sclerosis

Alemtuzumab for treating relapsing-remitting multiple sclerosis Alemtuzumab for treating relapsing-remitting multiple Issued: May 2014 guidance.nice.org.uk/ta NICE has accredited the process used by the Centre for Health Technology Evaluation at NICE to produce technology

More information

Medication Policy Manual. Topic: Plegridy, peginterferon beta-1a Date of Origin: December 12, 2014

Medication Policy Manual. Topic: Plegridy, peginterferon beta-1a Date of Origin: December 12, 2014 Medication Policy Manual Policy No: dru376 Topic: Plegridy, peginterferon beta-1a Date of Origin: December 12, 2014 Committee Approval Date: December 11, 2015 Next Review Date: December 2016 Effective

More information

Multiple Sclerosis (MS) Aprile Royal, Novartis Pharma Canada Inc. September 21, 2011 Toronto, ON

Multiple Sclerosis (MS) Aprile Royal, Novartis Pharma Canada Inc. September 21, 2011 Toronto, ON Multiple Sclerosis (MS) Aprile Royal, Novartis Pharma Canada Inc. September 21, 2011 Toronto, ON First-line DMTs Reduce Relapse Frequency by ~30% vs. Placebo Frequency of relapse with various DMTs, based

More information

Resources for the Primary Care Provider. Please print these out for reference

Resources for the Primary Care Provider. Please print these out for reference Resources for the Primary Care Provider Please print these out for reference Resources for providers American Academy of Neurology www.aan.com Provides education and resources, such as guidelines for clinical

More information

Medication Update. Acknowledgement

Medication Update. Acknowledgement Medication Update Multiple Sclerosis Limited Acknowledgement We acknowledge and pay respect to the traditional custodians past and present on whose lands we meet today. We acknowledge the deep feelings

More information

CNS DEMYLINATING DISORDERS

CNS DEMYLINATING DISORDERS CNS DEMYLINATING DISORDERS Multiple sclerosis A Dutch saint named Lidwina, who died in 1433, may have been one of the first known MS patients. After she fell while ice skating, she developed symptoms such

More information

Cost-effectiveness of teriflunomide (Aubagio ) for the treatment of adult patients with relapsing remitting multiple sclerosis

Cost-effectiveness of teriflunomide (Aubagio ) for the treatment of adult patients with relapsing remitting multiple sclerosis Cost-effectiveness of teriflunomide (Aubagio ) for the treatment of adult patients with relapsing remitting multiple sclerosis The NCPE has issued a recommendation regarding the cost-effectiveness of teriflunomide

More information

Treatment guidelines for relapsing MS and the two step approach for disease modifying therapy

Treatment guidelines for relapsing MS and the two step approach for disease modifying therapy Treatment guidelines for relapsing MS and the two step approach for disease modifying therapy Klaus Schmierer, PhD FRCP Blizard Institute, Barts and The London School of Medicine & Dentistry Barts Health

More information

New Developments in the Treatment and Management of Multiple Sclerosis

New Developments in the Treatment and Management of Multiple Sclerosis New Developments in the Treatment and Management of Multiple Sclerosis Myla D. Goldman, MD, MS For a CME/CEU version of this article, please go to www.namcp.org/cmeonline.htm, and then click the activity

More information

1. Comparative effectiveness of alemtuzumab

1. Comparative effectiveness of alemtuzumab Cost-effectiveness of alemtuzumab (Lemtrada ) for the treatment of adult patients with relapsing remitting multiple sclerosis with active disease defined by clinical or imaging features The NCPE has issued

More information

Multiple sclerosis disease-modifying drugs second line treatments

Multiple sclerosis disease-modifying drugs second line treatments Great Ormond Street Hospital for Children NHS Foundation Trust: Information for Families Multiple sclerosis disease-modifying drugs second line treatments The following information should be read in conjunction

More information

Growth in revenue from MS drugs has been driven largely by price increases over the last several years.

Growth in revenue from MS drugs has been driven largely by price increases over the last several years. March 4, 2013 Ben Weintraub, PhD Are Injectable MS Drugs Finished? Market Ready for Tecfidera Companies: Biogen (BIIB) Sanofi (SNY) Teva (TEVA) Novartis (NVS) Merck Serono Bayer Schering Products: Tecfidera

More information

Drug Class Review Disease-modifying Drugs for Multiple Sclerosis

Drug Class Review Disease-modifying Drugs for Multiple Sclerosis Drug Class Review Disease-modifying Drugs for Multiple Sclerosis Final Update 3 Report May 2016 The purpose of reports is to make available information regarding the comparative clinical effectiveness

More information

Information About Medicines for Multiple Sclerosis

Information About Medicines for Multiple Sclerosis Information About Medicines for Multiple Sclerosis Information About Medicines for Multiple Sclerosis What is multiple sclerosis? 1 Multiple sclerosis (MS) is a lifelong disease that affects your brain

More information

Original Policy Date

Original Policy Date MP 5.01.20 Tysabri (natalizumab) Medical Policy Section Prescription Drug Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date Local Policy/12:2013 Return to Medical Policy Index Disclaimer

More information

Teriflunomide for treating relapsing remitting multiple sclerosis

Teriflunomide for treating relapsing remitting multiple sclerosis Teriflunomide for treating relapsing remitting multiple Issued: January 2014 last modified: June 2014 guidance.nice.org.uk/ta NICE has accredited the process used by the Centre for Health Technology Evaluation

More information

The MS Disease- Modifying Drugs. Gener al information

The MS Disease- Modifying Drugs. Gener al information The MS Disease- Modifying Drugs Gener al information Current as of October 30, 2009. This online version is updated as breaking news requires. If you have downloaded and printed a copy from the web, please

More information

Advanced medicine conference. Monday 20 Tuesday 21 June 2016

Advanced medicine conference. Monday 20 Tuesday 21 June 2016 Advanced medicine conference Monday 20 Tuesday 21 June 2016 Relapsing Multiple Sclerosis: new and emerging treatments Jeremy Chataway Queen Square MS Centre National Hospital for Neurology and Neurosurgery,

More information

Relapsing-remitting multiple sclerosis Ambulatory with or without aid

Relapsing-remitting multiple sclerosis Ambulatory with or without aid AVONEX/BETASERON/COPAXONE/EXTAVIA/GILENYA/REBIF/TYSABRI Applicant must be covered on an Alberta Government sponsored drug program. Page 1 of 5 PATIENT INFMATION Surname First Name Middle Initial Sex Date

More information

Two-Year Phase III Data Presented at AAN 61st Annual Meeting Show Positive Outcome of Cladribine Tablets in Patients with Multiple Sclerosis

Two-Year Phase III Data Presented at AAN 61st Annual Meeting Show Positive Outcome of Cladribine Tablets in Patients with Multiple Sclerosis Your contact News Release Barbara Fry Phone +1 905 919 0163 April 29/30, 2009 Two-Year Phase III Data Presented at AAN 61st Annual Meeting Show Positive Outcome of Cladribine Tablets in Patients with Multiple

More information

INITIATING ORAL AUBAGIO (teriflunomide) THERAPY

INITIATING ORAL AUBAGIO (teriflunomide) THERAPY FOR YOUR PATIENTS WITH RELAPSING FORMS OF MS INITIATING ORAL AUBAGIO (teriflunomide) THERAPY WARNING: HEPATOTOXICITY AND RISK OF TERATOGENICITY Severe liver injury including fatal liver failure has been

More information

The Nuts and Bolts of Multiple Sclerosis. Rebecca Milholland, M.D., Ph.D. Center for Neurosciences

The Nuts and Bolts of Multiple Sclerosis. Rebecca Milholland, M.D., Ph.D. Center for Neurosciences The Nuts and Bolts of Multiple Sclerosis Rebecca Milholland, M.D., Ph.D. Center for Neurosciences Objectives Discuss which patients are at risk for Multiple Sclerosis Discuss the diagnostic criteria for

More information

Supplementary appendix

Supplementary appendix Supplementary appendix This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: Gold R, Giovannoni G, Selmaj K, et al, for

More information

fingolimod (as hydrochloride), 0.5mg hard capsules (Gilenya ) SMC No. (763/12) Novartis Pharmaceuticals UK Ltd

fingolimod (as hydrochloride), 0.5mg hard capsules (Gilenya ) SMC No. (763/12) Novartis Pharmaceuticals UK Ltd fingolimod (as hydrochloride), 0.5mg hard capsules (Gilenya ) SMC No. (763/12) Novartis Pharmaceuticals UK Ltd 10 February 2012 The Scottish Medicines Consortium (SMC) has completed its assessment of the

More information

Understanding your Tecfidera treatment

Understanding your Tecfidera treatment Understanding your Tecfidera treatment Information for patients who have been prescribed treatment with Tecfidera. (dimethyl fumarate) Contents About Multiple Sclerosis (MS) What is MS? Symptoms of MS

More information

Understanding your Tecfidera treatment

Understanding your Tecfidera treatment Understanding your Tecfidera treatment Information for patients who have been prescribed treatment with Tecfidera. (dimethyl fumarate) Contents About Multiple Sclerosis (MS) What is MS? Symptoms of MS

More information

The Immunopathogenesis of Relapsing MS

The Immunopathogenesis of Relapsing MS The Immunopathogenesis of Relapsing MS Olaf Stüve, M.D., Ph.D. Neurology Section VA North Texas Health Care System Dallas VA Medical Center Departments of Neurology and Neurotherapeutics University of

More information

Patient Group Input to CADTH

Patient Group Input to CADTH Patient Group Input to CADTH Section 1 General Information Name of the drug CADTH is reviewing and indication(s) of interest Name of patient group/author of submission Patient group s contact information:

More information

Multiple Sclerosis - Relapsing and Remissioning

Multiple Sclerosis - Relapsing and Remissioning DISEASE-MODIFYING THERAPIES IN RELAPSING-REMITTING MULTIPLE SCLEROSIS* Benjamin M. Greenberg, MD, MHS ABSTRACT Four major disease-modifying therapies are discussed within the context of relapsing and remitting

More information

alemtuzumab, 12mg, concentrate for solution for infusion (Lemtrada ) SMC No. (959/14) Genzyme

alemtuzumab, 12mg, concentrate for solution for infusion (Lemtrada ) SMC No. (959/14) Genzyme alemtuzumab, 12mg, concentrate for solution for infusion (Lemtrada ) SMC No. (959/14) Genzyme 04 April 2014 (Issued 06 June 2014) The Scottish Medicines Consortium (SMC) has completed its assessment of

More information

Treatment in Relapsing MS: Choosing Among the Options. Donald Negroski, MD

Treatment in Relapsing MS: Choosing Among the Options. Donald Negroski, MD Treatment in Relapsing MS: Choosing Among the Options Donald Negroski, MD Disclosures Research Grants Educational activities and lectures Consulting or other services including Continuing Medical Education

More information

Teriflunomide (Aubagio) 14mg once daily tablet

Teriflunomide (Aubagio) 14mg once daily tablet Teriflunomide (Aubagio) 14mg once daily tablet Exceptional healthcare, personally delivered Your Consultant Neurologist has suggested that you may benefit from treatment with Teriflunomide. The decision

More information

Fingolimod: Viruses and Vaccines

Fingolimod: Viruses and Vaccines Fingolimod: Viruses and Vaccines State of the Art 2014 Luzern Tobias Derfuss Neurologische Klinik und Poliklinik Universitätsspital Basel Fingolimod prevents lymphocyte egress from lymph nodes Fingolimod

More information

Progress in the field: therapeutic improvements for all patients?

Progress in the field: therapeutic improvements for all patients? Progress in the field: therapeutic improvements for all patients? Krzysztof Selmaj, Department of Neurology, Medical University of Lodz, PL Warsaw 15 May, 2015 Main features of MS Inflammation Demyelination

More information

Medication Policy Manual. Topic: Betaseron, Extavia, interferon beta-1b Date of Origin: June 18, 2004

Medication Policy Manual. Topic: Betaseron, Extavia, interferon beta-1b Date of Origin: June 18, 2004 Medication Policy Manual Policy No: dru108 Topic: Betaseron, Extavia, interferon beta-1b Date of Origin: June 18, 2004 Committee Approval Date: December 12, 2014 Next Review Date: December 2015 Effective

More information

Literature Scan: Oral Multiple Sclerosis Drugs

Literature Scan: Oral Multiple Sclerosis Drugs Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119

More information

Disease modifying drug therapy

Disease modifying drug therapy Disease modifying drug therapy what you need to know Third Edition Karen Alldus Simon Webster SECTION 2 We hope you find the information in this book helpful. If you would like to speak with someone about

More information

A blood sample will be collected annually for up to 2 years for JCV antibody testing.

A blood sample will be collected annually for up to 2 years for JCV antibody testing. Mellen Center Currently Enrolling Non-Treatment Trials STRATIFY-2 JCV Antibody Program in Patients with Relapsing Multiple Sclerosis Receiving or Considering Treatment with Tysabri Primary Investigator:

More information

Future therapies in multiple sclerosis

Future therapies in multiple sclerosis Neurology Asia 2008; 13 : 189 193 Future therapies in multiple sclerosis David Bates Department of Neurology, University of Newcastle upon Tyne, UK Abstract It is now 15 years since the first disease modifying

More information

Treatments-related side effects

Treatments-related side effects Treatments-related side effects MS: from the diagnosis to the disease management MSc, MD, José Flores Rivera Instituto Nacional de Neurología y Neurocirugía Safety issues: beta interferon Depression/suicidal

More information

Novel therapeutic approaches in multiple sclerosis Neuroprotective and remyelinating agents, the future of clinical trials in MS?

Novel therapeutic approaches in multiple sclerosis Neuroprotective and remyelinating agents, the future of clinical trials in MS? Novel therapeutic approaches in multiple sclerosis Neuroprotective and remyelinating agents, the future of clinical trials in MS? Marie Trad, M.D., Lynne Hughes, Cathy VanBelle, Amy Del Medico 3rd International

More information

Journal of Central Nervous System Disease

Journal of Central Nervous System Disease Journal of Central Nervous System Disease Expert Review Open Access Full open access to this and thousands of other papers at http://www.la-press.com. New and Emerging Disease-Modifying Therapies for Relapsing-Remitting

More information

Declaration of Conflicts of Interests

Declaration of Conflicts of Interests Toronto Neurology Update Multiple Sclerosis A Review Liesly Lee MSc, MD, FRCPC Associate Professor of Medicine (Neurology) Sunnybrook HSC University of Toronto October, 2015 Declaration of Conflicts of

More information

Dimethyl fumarate for treating relapsing-remitting multiple sclerosis

Dimethyl fumarate for treating relapsing-remitting multiple sclerosis Dimethyl fumarate for treating relapsing-remitting multiple Issued: August 2014 guidance.nice.org.uk/ta320 NICE has accredited the process used by the Centre for Health Technology Evaluation at NICE to

More information

Dimethyl fumarate for treating relapsing remitting multiple sclerosis

Dimethyl fumarate for treating relapsing remitting multiple sclerosis NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Final appraisal determination Dimethyl fumarate for treating relapsing remitting multiple sclerosis This guidance was developed using the single technology

More information

Pharmacologic Therapies for Multiple Sclerosis: From injectable to oral agents

Pharmacologic Therapies for Multiple Sclerosis: From injectable to oral agents Pharmacologic Therapies for Multiple Sclerosis: From injectable to oral agents KIRANPAL SINGH SANGHA, PHARM.D. CLINICAL PHARMACY SPECIALIST CNS THE UNIVERSITY OF CINCINNATI MEDICAL CENTER Objectives List

More information

Eastern Health MS Service. Tysabri Therapy. Information for People with MS and their Families

Eastern Health MS Service. Tysabri Therapy. Information for People with MS and their Families Eastern Health MS Service Tysabri Therapy Information for People with MS and their Families The Eastern Health MS Service has developed this information for you as a guide through what will happen to you

More information

Information about medicines for multiple sclerosis

Information about medicines for multiple sclerosis Information about medicines for multiple sclerosis Information about medicines for multiple sclerosis What is multiple sclerosis? 1 Multiple sclerosis (MS) is a lifelong disease that affects your brain

More information

ALEMTUZUMAB (LEMTRADA ) CLINICIAN INFORMATION

ALEMTUZUMAB (LEMTRADA ) CLINICIAN INFORMATION What is the medication? Generic: alemtuzumab Brand name: Lemtrada December 2014 Has the medication received US Food and Drug Administration (FDA) approval? If so, what are the indications and uses? Yes.

More information

Is the Grass Really Greener with New Oral Multiple Sclerosis Treatments? A Clinical Debate

Is the Grass Really Greener with New Oral Multiple Sclerosis Treatments? A Clinical Debate Is the Grass Really Greener with New Oral Multiple Sclerosis Treatments? A Clinical Debate Elizabeth Sebranek Evans, PharmD, BCPS, CGP Alana Whittaker, PharmD, BCPS Roseman University of Health Sciences

More information